FierceBiotech1d
Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from Denali
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
BioSpace22h
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
Business Wire2d
CI Financial Announces Receipt of Interim Court Order and Addition of Holdco Alternative to Plan of Arrangement with Mubadala Capital
CI Financial receives an interim court order concerning the transaction under which CI shares will be acquired by an ...
STAT23h
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...
CI Financial gets interim court order for shareholder meeting on Mubadala deal
CI Financial (TSX:CIX:CA) (OTCPK:CIXXF) received an interim order from the Ontario Superior Court of Justice that authorizes, ...
STAT22h
East Asians under-represented in biopharma leadership
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
CI Financial Advances Mubadala Arrangement with Holdco Option
The latest announcement is out from CI Financial ( (TSE:CIX) ).